Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer
文献类型：期刊论文
| 作者 | Zhou, Fengqi2,3; Gao, Jing3,4; Xu, Zhiai2; Li, Tianliang3; Gao, Ang3; Sun, Fang3; Wang, Fengyang4; Wang, Weiqi3; Geng, Yong3 ; Zhang, Fan1
|
| 刊名 | NANO TODAY
 |
| 出版日期 | 2021-02-01 |
| 卷号 | 36页码:12 |
| ISSN号 | 1748-0132 |
| 关键词 | Tumor microenvironment Prodrug nanovesicles Cancer immunotherapy Immunogenic cell death Adaptive immune resistance |
| DOI | 10.1016/j.nantod.2020.101025 |
| 通讯作者 | Xu, Zhiai(zaxu@ecnu.chem.ac.cn) ; Yu, Haijun(hjyu@simm.ac.cn) |
| 英文摘要 | Chemotherapy by certain types of anticancer drugs (e.g., doxorubicin (DOX) and oxaliplatin (OXA)) can elicit antitumor immune response by promoting immunogenic cell death (ICD) of the tumor cells. However, ICD-based chemoimmunotherapy is severely impaired by non-specific distribution of the chemotherapeutics and T lymphocyte-induced immune resistance. To address these challenges, we herein reported a sequential prodrug nanovesicle specifically designed for enhancing drug delivery to the tumor tissues and reducing the immunological resistance of the tumor cells. The prodrug nanovesicles were composed of fluorophore IR-1061, chemotherapeutic DOX, and a prodrug of bromodomain-containing protein 4 inhibitor (BRD4i) JQ1. Upon 1064 nm laser irradiation, IR-1061 induced mild hyperthermia for triggering NIR-II fluorescence imaging-guided drug release at the tumor site. DOX promoted intratumoral infiltration of the cytotoxic T lymphocytes (CTLs) by inducing ICD of the tumor cells. Meanwhile, JQ1 blocked IFN-gamma-induced upregulation of programmed death ligand I (PD-L1) to reduce the adaptive immune resistance. In combination with laser irradiation, the prodrug nanovesicles remarkably inhibited growth of both 4T1 breast and CT26 colorectal tumors, and suppressed lung metastasis of 4T1 breast tumor in the immunocompetent mouse model. The prodrug nanoplatform reported herein might provide a novel insight for promoting chemoimmunotherapy of cancers by overcoming PD-L1-dependent immune evasion through the IFN-gamma-BRD4-PD-L1 axis. (C) 2020 Elsevier Ltd. All rights reserved. |
| 资助项目 | National Natural Science Foundation of China[22074043] ; National Natural Science Foundation of China[51873228] ; International Cooperation Project of Science and Technology Commission of Shanghai Municipality[20430711800] ; Shanghai Post-Doctoral Excellence Program[2019116] ; Fudan University, CAS[FU-SIMM-20182006] ; Shanghai Institute of Materia Medica, CAS[FU-SIMM-20182006] ; Open Fund of the State Key Laboratory of Drug Research[SIMM2004KF-04] |
| WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science |
| 语种 | 英语 |
| 出版者 | ELSEVIER SCI LTD |
| WOS记录号 | WOS:000637808000017 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296495]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xu, Zhiai; Yu, Haijun |
| 作者单位 | 1.Fudan Univ, Dept Chem, Shanghai 200438, Peoples R China 2.East China Normal Univ, Sch Chem & Mol Engn, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, State Key Lab Drug Res & Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 4.Tongji Univ, Ultrasound Res & Educ Inst, Dept Med Ultrasound,Shanghai Peoples Hosp 10, Sch Med,Canc Ctr, Shanghai 200072, Peoples R China 5.Univ Queensland, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld 4072, Australia |
| 推荐引用方式 GB/T 7714 | Zhou, Fengqi,Gao, Jing,Xu, Zhiai,et al. Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer[J]. NANO TODAY,2021,36:12. |
| APA | Zhou, Fengqi.,Gao, Jing.,Xu, Zhiai.,Li, Tianliang.,Gao, Ang.,...&Yu, Haijun.(2021).Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer.NANO TODAY,36,12. |
| MLA | Zhou, Fengqi,et al."Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer".NANO TODAY 36(2021):12. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。